Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.70 |
| ▸ | DRD4 | P21917 | 8/20 | 0.70 |
| ▸ | DRD3 | P35462 | 7/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4003845 | 0.81 | HSD17B10 (0.77) | DRD2DRD4DRD3POLBALDH1A1 | |
| SCHEMBL4002846 | 0.80 | DRD2 (1.00) | DRD2DRD4DRD3 | |
| SCHEMBL19851992 | 0.80 | TSHR (0.64) | POLBALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4002378 | 0.79 | DRD4 (0.69) | DRD2DRD4DRD3POLBALDH1A1 | |
| SCHEMBL4002664 | 0.78 | DRD2 (1.00) | DRD2DRD4DRD3POLBALDH1A1 | |
| SCHEMBL5577914 | 0.78 | CHRM3 (0.59) | DRD2DRD4DRD3POLBALDH1A1 | |
| SCHEMBL10757967 | 0.76 | MEN1 (0.70) | ALDH1A1SMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL29799167 | 0.76 | HDAC1 (0.65) | SMN1; SMN2KDM4EMAPT | |
| SCHEMBL28742970 | 0.76 | HDAC1 (0.65) | SMN1; SMN2KDM4EMAPT | |
| SCHEMBL2774517 | 0.76 | DRD4 (0.64) | DRD2DRD4DRD3POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | DRD2 69/4885DRD4 237/4885DRD3 290/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | DRD2 69/4885DRD4 237/4885DRD3 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.